Marie-Claire Peakman, MRPHARMS, PHD is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Curve Therapeutics, DEM Biopharma, Greywolf Therapeutics, Mediar Therapeutics, Mozart Therapeutics, Normunity, TRIMTECH Therapeutics and a stealth company. She is also responsible for managing our investment in the Andera Partners’ BioDiscovery 7 Fund and is a member of the advisory board for the CT Bioscience Innovation Fund.

Marie-Claire brings over 25 years of experience at Pfizer, leading platform technology groups that support small molecule programs from idea to development candidate selection across all therapeutic areas. These teams, including the Primary Pharmacology Group which she founded in 2009, played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. Her experience extends to compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She has multiple roles on non-profit boards in the community.

Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal Pharmaceutical Society.

Email: [email protected]